Consensus Simulations Plus, Inc.

Stocks

SLP

US8292141053

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 01:30:00 15/09/2026 am IST			5-day change	1st Jan Change
18.42 ^USD	0.00%		-0.05%	+1.04%

20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
10/07	Simulations Plus Fiscal Q3 Adjusted Earnings Decline, Revenue Rises	MT

Evolution of the Average Target: Simulations Plus, Inc.

Evolution of the Target Price: Simulations Plus, Inc.

Changes in Analyst Recommendations: Simulations Plus, Inc.

72ef6298c4274c4629e7fef96ed.uld2K6NIiBF2bMAUhLi9N1yX--N_UTSpchx9xeGEPF4.1Q47H8B-xF9EBaR4woD_XTbAtM4nHQX9GU9PgbHDU2__PzFGxxD-UBco8A~ca1e729b7744224a92d277ce36af2f39

Analysts' recommendations: Simulations Plus, Inc.

18/06	Craig-Hallum Downgrades Simulations Plus to Hold From Buy, Adjusts Price Target to $18.50 From $31	MT
17/06	William Blair Downgrades Simulations Plus to Market Perform From Outperform	MT
18/12	BTIG Research Downgrades Simulations Plus to Neutral From Buy	MT
30/25/30	TD Cowen Initiates Simulations Plus at Hold With $16 Price Target	MT
15/25/15	KeyBanc Downgrades Simulations Plus to Sector Weight From Overweight, Removes $25 Price Target	MT
07/25/07	BTIG Adjusts Price Target on Simulations Plus to $25 From $41, Maintains Buy Rating	MT
08/25/08	KeyBanc Lowers Price Target on Simulations Plus to $35 From $40, Keeps Overweight Rating	MT
15/24/15	Stephens Initiates Simulations Plus at Overweight With $39 Price Target	MT
29/24/29	KeyBanc Initiates Simulations Plus at Overweight With $47 Price Target	MT
16/24/16	JMP Securities Initiates Simulations Plus at Market Perform	MT
03/24/03	Top Decliners	MT
28/24/28	William Blair Initiates Simulations Plus at Outperform	MT
13/24/13	Craig-Hallum Raises Price Target on Simulations Plus to $56 From $51, Maintains Buy Rating	MT
13/24/13	Oppenheimer Adjusts Price Target on Simulations Plus to $65 From $55, Maintains Outperform Rating	MT
26/23/26	Oppenheimer Adjusts Simulations Plus Price Target to $55 From $67, Maintains Outperform Rating	MT
21/23/21	Oppenheimer Raises Simulations' Plus Price Target to $67 From $65, Maintains Outperform Rating	MT
09/23/09	BTIG Initiates Simulations Plus at Buy With $55 Price Target	MT
22/22/22	Sidoti Cuts Price Target on Simulations Plus to $44 From $56, Keeps Neutral Rating	MT
27/22/27	Oppenheimer Adjusts Simulations Plus Price Target to $65 From $75, Maintains Outperform Rating	MT
29/22/29	Raymond James Adjusts Price Target on Simulations Plus to $70 From $54, Keeps Outperform Rating	MT
27/22/27	Raymond James Adjusts Simulations Plus Price Target to $70 From $54, Maintains Outperform Rating	MT
07/22/07	Craig Hallum Raises Simulations Plus' Price Target to $60 From $55, Buy Rating Kept	MT
26/21/26	Craig-Hallum Upgrades Simulations Plus to Buy From Hold; Price Target is $53	MT
13/21/13	Simulations Plus : Oppenheimer Adjusts Simulations Plus PT to $75 From $85 Following Fiscal Q3 Miss, Maintains Outperform Rating	MT
13/21/13	Simulations Plus : Craig-Hallum Adjusts Price Target on Simulations Plus to $65 From $74, Maintains Hold Rating	MT

More recommendations

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
SIMULATIONS PLUS, INC.	-			-6.35%
VEEVA SYSTEMS INC.				+11.9%
PRO MEDICUS LIMITED				+22.41%
SECTRA AB				+15.72%
HEARTFLOW, INC.				-9.61%
GENERATE BIOMEDICINES, INC.				+68.75%
OMNICELL, INC.				+72.66%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.		-		+60.66%
ARBUTUS BIOPHARMA CORPORATION		-	-	+7.21%
Average				+27.04%
Weighted average by Cap.				+16.20%